Clinical Trial Update: Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus [Phase 2]

View source ↗

Summary

Open-label Phase 2 extension study evaluating Neramexane for congenital and acquired nystagmus has been terminated. The update summarizes safety and efficacy ob…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Nystagmus
• Congenital Nystagmus
• Multiple Sclerosis

Drugs mentioned

• Neramexane (neramexane)

Snippet

Sponsor: Merz Pharmaceuticals GmbH | Conditions: Nystagmus, Congenital, Nystagmus, Acquired | Phase 2 | Status: TERMINATED